• Zelluna’s Q3 2026 pretax loss narrowed 26% year-over-year to NOK 28.97 million.
• Quarter-end cash fell 30% from Q2 2026 to NOK 60.38 million, with cash runway into Q3 2027.
• Two patients received Dose Level 1 in the ZIMA-101 trial, with no dose-limiting toxicities observed to date.
• Third-patient dosing is planned for Q4 2026; Dose Level 2 recruitment and dosing should finish in Q1–early Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zelluna ASA published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.